Neogenomics (NEO) Cash & Equivalents (2010 - 2026)

Neogenomics (NEO) has reported Cash & Equivalents for 17 consecutive years, with $145.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Equivalents fell 5.94% year-over-year to $145.5 million; the trailing twelve-month figure through Jun 2026 stood at $145.5 million (down 5.94% YoY), and the FY2025 full-year result was $159.6 million, down 56.51% from the prior year.
• Cash & Equivalents steadied at $145.5 million in Q2 2026 per NEO's latest filing, from $146.1 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $367.0 million in Q4 2024 and bottomed at $145.5 million in Q2 2026.
• Historically, Cash & Equivalents has averaged $270.3 million across 5 years, with a median of $286.4 million in 2022.
• The sharpest annual moves came in 2023 and 2026: Cash & Equivalents soared 30.13% in 2023, then sank 57.79% in 2026.
• Over 5 years, Cash & Equivalents stood at $263.2 million in 2022, then surged by 30.13% to $342.5 million in 2023, then gained by 7.16% to $367.0 million in 2024, then sank by 56.51% to $159.6 million in 2025, then declined by 8.82% to $145.5 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $145.5 million, $146.1 million, and $159.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.